FDA gives go-ahead to UK drugmaker’s multiple myeloma treatment Blenrep
Luke Miels is known for commercial execution and successful bolt-on deals
UK drugmaker’s chief commercial officer Luke Miels will take over on January 1
Eli Lilly, Merck and AstraZeneca have all said in recent weeks that they plan to roll back investment
US president threatens to ‘deploy every tool in our arsenal’ to protect Americans from ‘abusive drug prices’
UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
Shares in UK pharma group fall after advisory committee votes that Blenrep benefits do not outweigh risks
Oxford research shows adjuvant chemicals included in vaccinations may enhance their antiviral effect
Drugmaker says it can harness technology and change supply chain to guard against possible new levies
UK drugmaker says Emma Walmsley is underpaid compared with global competitors as it abandons diversity targets
US hedge fund shorts drugmaker as shares trade below price of a decade ago
Hedge fund’s short position is the biggest in the FTSE 100 group in more than a decade
Drugmaker pins hopes on launch of new medicines but key point is to avoid re-traumatising investors
UK pharma group raises long-term annual sales forecast to more than £40bn by 2031
IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official
UK pharma group posts ‘statistically significant’ trial results for Blenrep when combined with another treatment
UK pharma group’s shares fall 3% after third-quarter revenues miss expectations
Agreement over heartburn medicine should help to resolve concerns hanging over UK drugmaker
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain
Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product
GSK and AstraZeneca plan final trials to upgrade propellants that cause much of the sector’s carbon footprint
Analysts often err on side of extreme caution — but overreactions can generate potential opportunities
UK pharmaceutical group forecasts 7-9% revenue growth this year on strong performance from cancer and HIV drugs
